Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in two major investor conferences in March 2025. The company will be featured in:
- A fireside chat at the Leerink Global Biopharma Conference on Wednesday, March 12 at 9:20 a.m. ET
- A fireside chat at the UBS Virtual CNS Day on Monday, March 17 at 8:30 a.m. ET
Both events will be accessible through live webcasts on Avadel's Investor Relations website (investors.avadel.com), with recordings remaining available for 90 days after each conference.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato la sua prossima partecipazione a due importanti conferenze per investitori a marzo 2025. L'azienda sarà presente in:
- Una chiacchierata informale alla Leerink Global Biopharma Conference mercoledì 12 marzo alle 9:20 a.m. ET
- Una chiacchierata informale al UBS Virtual CNS Day lunedì 17 marzo alle 8:30 a.m. ET
Entrambi gli eventi saranno accessibili tramite webcast dal vivo sul sito web delle Relazioni con gli Investitori di Avadel (investors.avadel.com), con le registrazioni disponibili per 90 giorni dopo ogni conferenza.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha anunciado su próxima participación en dos importantes conferencias para inversores en marzo de 2025. La empresa estará presente en:
- Una charla informal en la Leerink Global Biopharma Conference el miércoles 12 de marzo a las 9:20 a.m. ET
- Una charla informal en el UBS Virtual CNS Day el lunes 17 de marzo a las 8:30 a.m. ET
Ambos eventos serán accesibles a través de transmisiones en vivo en el sito web de Relaciones con Inversores de Avadel (investors.avadel.com), con grabaciones disponibles durante 90 días después de cada conferencia.
Avadel Pharmaceuticals (Nasdaq: AVDL)는 2025년 3월에 열리는 두 개의 주요 투자자 회의에 참여할 예정이라고 발표했습니다. 회사는 다음과 같은 행사에 참여합니다:
- 3월 12일 수요일 오전 9시 20분 ET에 열리는 Leerink Global Biopharma Conference에서의 대담
- 3월 17일 월요일 오전 8시 30분 ET에 열리는 UBS Virtual CNS Day에서의 대담
두 이벤트 모두 Avadel의 투자자 관계 웹사이트 (investors.avadel.com)를 통해 실시간 웹캐스트로 접근 가능하며, 각 회의 후 90일 동안 녹화본을 이용할 수 있습니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé sa prochaine participation à deux grandes conférences pour investisseurs en mars 2025. L'entreprise sera présente lors des événements suivants :
- Une discussion informelle à la Leerink Global Biopharma Conference le mercredi 12 mars à 9h20 ET
- Une discussion informelle au UBS Virtual CNS Day le lundi 17 mars à 8h30 ET
Les deux événements seront accessibles via des webdiffusions en direct sur le site Web des Relations avec les Investisseurs d'Avadel (investors.avadel.com), avec des enregistrements disponibles pendant 90 jours après chaque conférence.
Avadel Pharmaceuticals (Nasdaq: AVDL) hat seine bevorstehende Teilnahme an zwei wichtigen Investorenkonferenzen im März 2025 angekündigt. Das Unternehmen wird an folgenden Veranstaltungen teilnehmen:
- Ein informelles Gespräch auf der Leerink Global Biopharma Conference am Mittwoch, den 12. März um 9:20 Uhr ET
- Ein informelles Gespräch am UBS Virtual CNS Day am Montag, den 17. März um 8:30 Uhr ET
Beide Veranstaltungen werden über Live-Webcasts auf der Investor Relations-Website von Avadel (investors.avadel.com) zugänglich sein, wobei die Aufzeichnungen 90 Tage nach jeder Konferenz verfügbar bleiben.
- None.
- None.
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.
- UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET.
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When is Avadel Pharmaceuticals (AVDL) presenting at the Leerink Global Biopharma Conference in March 2025?
How long will the webcasts of AVDL's March 2025 investor conferences be available?
What time is Avadel Pharmaceuticals (AVDL) presenting at the UBS Virtual CNS Day?
Where can investors watch Avadel Pharmaceuticals' (AVDL) March 2025 conference presentations?
